How can vaccines contribute to solving the antimicrobial resistance problem?

mBio

Volumn 7, Issue 3, 2016, Pages

  Lipsitch, Marc ^a   Siber, George R ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b ClearPath Vaccines Company (CVC)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPICILLIN; BCG VACCINE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FLORFENICOL; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; LINEZOLID; MALARIA VACCINE; MEROPENEM; MONOCLONAL ANTIBODY; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLYMYXIN; PSEUDOMONAS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SALMONELLOSIS VACCINE; SHIGELLA VACCINE; STAPHYLOCOCCUS VACCINE; TIMENTIN; VACCINE; VANCOMYCIN; VIRULENCE FACTOR; ANTIINFECTIVE AGENT; BACTERIAL VACCINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ASYMPTOMATIC INFECTION; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BORDETELLA PERTUSSIS; DRUG USE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS MENINGITIS; HEALTHCARE ASSOCIATED INFECTION; HERD IMMUNITY; HUMAN; INAPPROPRIATE PRESCRIBING; INFLUENZA; INVASIVE CANDIDIASIS; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VACCINE FAILURE; ADVERSE EFFECTS; BACTERIAL INFECTIONS; DRUG EFFECTS; HAEMOPHILUS INFLUENZAE; MICROBIOLOGY; NEISSERIA MENINGITIDIS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; NEISSERIA MENINGITIDIS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84978975531     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00428-16     Document Type: Review

References (87)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
2. Review on Antimicrobial Resistance. 2014. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. London, United Kingdom. http://amr-review.org/sites/default/files/AMR%20Review %20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health %20and%20wealth%20of%20nations_1.pdf.
3. White House. 2014. National strategy for combating antibiotic-resistant bacteria. The White House, Washington, DC. https://www.white house.gov/sites/default/files/docs/carb_national_strategy.pdf.
4. World Health Organization. 2015. Global action plan on antimicrobial resistance. World Health Organization, Geneva, Switzerland.
5. Review on Antimicrobial Resistance. 2016. Tackling drug-resistant infections globally: final report and recommendations. London, United Kingdom. http://amr-review.org/sites/default/files/160518_Final%20paper _with%20cover.pdf.
6. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, Davies S. 2016. Access to effective antimicrobials: a worldwide challenge. Lancet 387: 168-175. http://dx.doi.org/10.1016/S0140-6736(15)00474-2.
7. National Vaccine Advisory Consortium. 2016. A call for greater consideration for the role of vaccines in national strategies to combat antibioticresistant bacteria: recommendations from the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 10, 2015. Public Health Rep 131: 11-16.
8. Review on Antimicrobial Resistance. 2016. Vaccines and alternative approaches: reducing our dependence on antimicrobials. The Review on Antimicrobial Resistance Chaired by Jim O’Neill, London, United Kingdom. http://amr-review.org/sites/default/files/Vaccines%20and%20alternatives _v4_LR.pdf.
9. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S. 2013. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 13: 1057-1098. http://dx.doi.org/10.1016/S1473-3099(13)70318-9.
10. Chang HH, Cohen T, Grad YH, Hanage WP, O’Brien TF, Lipsitch M. 2015. Origin and proliferation of multiple-drug resistance in bacterial pathogens. Microbiol Mol Biol Rev 79: 101-116. http://dx.doi.org/10.1128/MMBR.00039-14.
11. Fine PEM. 1993. Herd immunity: history, theory, practice. Epidemiol Rev 15: 265-302.
12. Levin BR, Cornejo OE. 2009. The population and evolutionary dynamics of homologous gene recombination in bacterial populations. PLoS Genet 5: e1000601. http://dx.doi.org/10.1371/journal.pgen.1000601.
13. Levin BR, Stewart FM, Rice VA. 1979. The kinetics of conjugative plasmid transmission: fit of a simple mass action model. Plasmid 2: 247-260. http://dx.doi.org/10.1016/0147-619X(79)90043-X.
14. Murray BE. 1992. Problems and dilemmas of antimicrobial resistance. Pharmacotherapy 12: 86S-93S.
15. Peltola H, Aavitsland P, Hansen KG, Jónsdóttir KE, Nøkleby H, Romanus V. 1999. Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 179: 223-229. http://dx.doi.org/10.1086/314535.
16. John TJ, Cherian T, Raghupathy P. 1998. Haemophilus influenzae disease in children in India: a hospital perspective. Pediatr Infect Dis J 17(9 Suppl): S169-S171. http://dx.doi.org/10.1097/00006454-199809001-00015.
17. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG, Active Bacterial Core Surveillance of the Emerging Infections Program Network. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354: 1455-1463. http://dx.doi.org/10.1056/NEJMoa051642.
18. Ladhani SN, Slack MP, Andrews NJ, Waight PA, Borrow R, Miller E. 2013. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 19: 61-68. http://dx.doi.org/10.3201/eid1901.120741.
19. Wilby KJ, Werry D. 2012. A review of the effect of immunization programs on antimicrobial utilization. Vaccine 30: 6509-6514. http://dx.doi.org/10.1016/j.vaccine.2012.08.031.
20. Lee GC, Reveles KR, Attridge RT, Lawson KA, Mansi IA, Lewis JS, II, Frei CR. 2014. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med 12: 96. http://dx.doi.org/10.1186/1741-7015-12-96.
21. Lipsitch M. 1999. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5: 336-345. http://dx.doi.org/10.3201/eid0503.990304.
22. Weinberger DM, Malley R, Lipsitch M. 2011. Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962-1973. http://dx.doi.org/10.1016/S0140-6736(10)62225-8.
23. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’Brien KL, Moore MR, Serotype Replacement Study Group. 2013. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLOS Med 10: e1001517. http://dx.doi.org/10.1371/journal.pmed.1001517.
24. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH, Pondo T, Rodgers L, McGee L, Beall B. 2015. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 15: 301-309. http://dx.doi.org/10.1016/S1473-3099(14)71081-3.
25. Dowell SF, Schwartz B, Phillips WR. 1998. Appropriate use of antibiotics for URIs in children: Part II. Cough, pharyngitis and the common cold. The Pediatric URI Consensus Team. Am Fam Physician 58: 1335-1342, 1345.
26. Link-Gelles R, Thomas A, Lynfield R, Petit S, Schaffner W, Harrison L, Farley MM, Aragon D, Nicols M, Kirley PD, Zansky S, Jorgensen J, Juni BA, Jackson D, Moore MR, Lipsitch M. 2013. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis 208: 1266-1273. http://dx.doi.org/10.1093/infdis/jit315.
27. Malley R, Anderson PW. 2012. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci U S A 109: 3623-3627. http://dx.doi.org/10.1073/pnas.1121383109.
28. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM, Finkelstein JA, Gerber JS, Hyun DY, Linder JA, Lynfield R, Margolis DJ, May LS, Merenstein D, Metlay JP, Newland JG, Piccirillo JF, Roberts RM, Sanchez GV, Suda KJ, Thomas A, Woo TM, Zetts RM, Hicks LA. 2016. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 315(17): 1864-1873.
29. Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, Knight TK, Hay JW, Doctor JN. 2016. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. JAMA 315: 562-570. http://dx.doi.org/10.1001/jama.2016.0275.
30. Misurski DA, Lipson DA, Changolkar AK. 2011. Inappropriate antibi-otic prescribing in managed care subjects with influenza. Am J Manag Care 17: 601-608.
31. Polgreen PM, Yang M, Laxminarayan R, Cavanaugh JE. 2011. Respiratory fluoroquinolone use and influenza. Infect Control Hosp Epidemiol 32: 706-709. http://dx.doi.org/10.1086/660859.
32. Kwong JC, Maaten S, Upshur RE, Patrick DM, Marra F. 2009. The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. Clin Infect Dis 49: 750-756. http://dx.doi.org/10.1086/605087.
33. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV Vaccine Consultation Expert Group. 2016. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine 34: 190-197. http://dx.doi.org/10.1016/j.vaccine.2015.05.093.
34. Du H, Chen L, Tang YW, Kreiswirth BN. 2016. Emergence of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae. Lancet Infect Dis 16: 287-288. http://dx.doi.org/10.1016/S1473-3099(16)00056-6.
35. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16: 161-168. http://dx.doi.org/10.1016/S1473-3099(15)00424-7.
36. Poolman JT, Wacker M. 2016. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J Infect Dis 213: 6-13. http://dx.doi.org/10.1093/infdis/jiv429.
37. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gramnegative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35: 736-755. http://dx.doi.org/10.1111/j.1574-6976.2011.00268.x.
38. Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M. 2005. Engineering N-linked protein glycosylation with diverseOantigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci U S A 102: 3016-3021. http://dx.doi.org/10.1073/pnas.0500044102.
39. Zhang F, Lu YJ, Malley R. 2013. Multiple antigen-presenting system (MAPS) to induce comprehensive B-and T-cell immunity. Proc Natl Acad Sci U S A 110: 13564-13569. http://dx.doi.org/10.1073/pnas.1307228110.
40. Rappuoli R. 2000. Reverse vaccinology. Curr Opin Microbiol 3: 445-450. http://dx.doi.org/10.1016/S1369-5274(00)00119-3.
41. Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, Veggi D, Smith S, Bertoldi I, Pastorello I, Ferlenghi I, Fontana MR, Frankel G, Mobley HL, Rappuoli R, Pizza M, Serino L, Soriani M. 2012. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. mBio 3: e00010-12. http://dx.doi.org/10.1128/mBio.00010-12.
42. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D. 2010. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 107: 9072-9077. http://dx.doi.org/10.1073/pnas.0915077107.
43. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. 2015. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313: 1719-1727. http://dx.doi.org/10.1001/jama.2015.3725.
44. Scully IL, Liberator PA, Jansen KU, Anderson AS. 2014. Covering all the bases: preclinical development of an effective Staphylococcus aureus vaccine. Front Immunol 5:. http://dx.doi.org/10.3389/fimmu.2014.00109.
45. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. 2012. Clostridium difficile: development of a novel candidate vaccine. Vaccine 30: 4307-4309. http://dx.doi.org/10.1016/j.vaccine.2012.01.056.
46. Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. 2014. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother 10: 170-183. http://dx.doi.org/10.4161/hv.26565.
47. Liu Y, Filler SG. 2011. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot Cell 10: 168-173. http://dx.doi.org/10.1128/EC.00279-10.
48. Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE, Hennessey JP. 2012. NDV-3, a recombinant alumadjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 30: 7594-7600. http://dx.doi.org/10.1016/j.vaccine.2012.10.038.
49. Thammavongsa V, Kim HK, Missiakas D, Schneewind O. 2015. Staphylococcal manipulation of host immune responses. Nat Rev Microbiol 13: 529-543. http://dx.doi.org/10.1038/nrmicro3521.
50. Fowler VG, Jr, Proctor RA. 2014. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect 20(Suppl 5): 66-75. http://dx.doi.org/10.1111/1469-0691.12570.
51. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. 2013. Vaccine review:"Staphylococcus aureus vaccines: problems and prospects". Vaccine 31: 2723-2730. http://dx.doi.org/10.1016/j.vaccine.2013.04.002.
52. DiGiandomenico A, Sellman BR. 2015. Antibacterial monoclonal antibodies: the next generation? Curr Opin Microbiol 27: 78-85. http://dx.doi.org/10.1016/j.mib.2015.07.014.
53. Warfel JM, Zimmerman LI, Merkel TJ. 2014. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 111: 787-792. http://dx.doi.org/10.1073/pnas.1314688110.
54. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH. 2013. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 9: e1003264. http://dx.doi.org/10.1371/journal.ppat.1003264.
55. RTS,S Clinical Trials Partnership. 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 31-45. http://dx.doi.org/10.1016/S0140-6736(15)60721-8.
56. Murphy TF. 2015. Vaccines for nontypeable Haemophilus influenzae: the future is now. Clin Vaccine Immunol 22: 459-466. http://dx.doi.org/10.1128/CVI.00089-15.
57. Unemo M. 2015. Current and future antimicrobial treatment of gonorrhoea-the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 15: 364. http://dx.doi.org/10.1186/s12879-015-1029-2.
58. Joice R, Lipsitch M. 2013. Targeting imperfect vaccines against drugresistance determinants: a strategy for countering the rise of drug resistance. PLoS One 8: e68940. http://dx.doi.o r g /1 0. 1 3 7 1 /journal.pone.0068940.
59. Tekle YI, Nielsen KM, Liu J, Pettigrew MM, Meyers LA, Galvani AP, Townsend JP. 2012. Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains. PLoS One 7: e50688. http://dx.doi.org/10.1371/journal.pone.0050688.
60. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’Brien KL, Moore MR, Serotype Replacement Study Group. 2013. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLOS Med 10: e1001517. http://dx.doi.org/10.1371/journal.pmed.1001517.
61. Wilson JN, Nokes DJ, Carman WF. 2000. Predictions of the emergence of vaccine-resistant hepatitis B in The Gambia using a mathematical model. Epidemiol Infect 124: 295-307. http://dx.doi.org/10.1017/S0950268800003605.
62. Ibarz-Pavón AB, Maclennan J, Andrews NJ, Gray SJ, Urwin R, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, Ala’aldeen D, Crook DW, Cann K, Harrison S, Cunningham R, Baxter D, Kaczmarski E, McCarthy ND, Jolley KA, Cameron JC. 2011. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis 204: 1046-1053. http://dx.doi.org/10.1093/infdis/jir466.
63. Queenan AM, Cassiday PK, Evangelista A. 2013. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 368: 583-584. http://dx.doi.org/10.1056/NEJMc1209369.
64. Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, Cassiday PK, Chiang CS, Dalby T, Fry NK, Gaillard ME, van Gent M, Guiso N, Hallander HO, Harvill ET, He Q, van der Heide HG, Heuvelman K, Hozbor DF, Kamachi K. 2014. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. mBio 5: e01074. http://dx.doi.org/10.1128/mBio.01074-14.
65. OttoM. 2012. MRSA virulence and spread. Cell Microbiol 14: 1513-1521. http://dx.doi.org/10.1111/j.1462-5822.2012.01832.x.
66. Queck SY, Khan BA, Wang R, Bach TH, Kretschmer D, Chen L, Kreiswirth BN, Peschel A, Deleo FR, Otto M. 2009. Mobile genetic element-encoded cytolysin connects virulence to methicillin resistance in MRSA. PLoS Pathog 5: e1000533. http://dx.doi.org/10.1371/journal.ppat.1000533.
67. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294. http://dx.doi.org/10.1084/jem.20072208.
68. Mitchell PK, Lipsitch M, Hanage WP. 2015. Carriage burden, multiple colonization and antibiotic pressure promote emergence of resistant vaccine escape pneumococci. Philos Trans R Soc Lond B Biol Sci 370: 20140342. http://dx.doi.org/10.1098/rstb.2014.0342.
69. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, Bentley SD, Hanage WP, Lipsitch M. 2013. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet 45: 656-663. http://dx.doi.org/10.1038/ng.2625.
70. Senna JP, Roth DM, Oliveira JS, Machado DC, Santos DS. 2003. Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach. Vaccine 21: 2661-2666. http://dx.doi.org/10.1016/S0264-410X(02)00738-7.
71. Zarantonelli ML, Antignac A, Lancellotti M, Guiyoule A, Alonso JM, Taha MK. 2006. Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice. J Antimicrob Chemother 57: 924-930. http://dx.doi.org/10.1093/jac/dkl066.
72. Ciofu O, Bagge N, Høiby N. 2002. Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactamresistant Pseudomonas aeruginosa in a rat model of chronic lung infection. APMIS 110: 881-891. http://dx.doi.org/10.1034/j.1600-0463.2002.1101207.x.
73. Kodali S, Vinogradov E, Lin F, Khoury N, Hao L, Pavliak V, Jones CH, Laverde D, Huebner J, Jansen KU, Anderson AS, Donald RG. 2015. A vaccine approach for the prevention of infections by multidrug-resistant Enterococcus faecium. J Biol Chem 290: 19512-19526. http://dx.doi.org/10.1074/jbc.M115.655852.
74. Al-Hamad A, Burnie J, Upton M. 2011. Enhancement of antibiotic susceptibility of Stenotrophomonas maltophilia using a polyclonal antibody developed against an ABC multidrug efflux pump. Can J Microbiol 57: 820-828. http://dx.doi.org/10.1139/w11-076.
75. Wu B, Xia C, Du X, Cao X, Shen J. 2006. Influence of anti-FloR antibody on florfenicol accumulation in florfenicol-resistant Escherichia coli and enzyme-linked immunosorbent assay for detection of florfenicol-resistant E. coli isolates. J Clin Microbiol 44: 378-382. http://dx.doi.org/10.1128/JCM.44.2.378-382.2006.
76. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. 2014. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6: 262ra155. http://dx.doi.org/10.1126/scitranslmed.3009655.
77. Secher T, Fas S, Fauconnier L, Mathieu M, Rutschi O, Ryffel B, Rudolf M. 2013. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLoS One 8: e73396. http://dx.doi.org/10.1371/journal.pone.0073396.
78. Hua L, Cohen TS, Shi Y, Datta V, Hilliard JJ, Tkaczyk C, Suzich J, Stover CK, Sellman BR. 2015. MEDI4893* promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother 59: 4526-4532. http://dx.doi.org/10.1128/AAC.00510-15
79. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J. 2006. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 74: 1016-1024. http://dx.doi.org/10.1128/IAI.74.2.1016-1024.2006.
80. Bugli F, Cacaci M, Martini C, Torelli R, Posteraro B, Sanguinetti M, Paroni Sterbini F. 2013. Human monoclonal antibody-based therapy in the treatment of invasive candidiasis. Clin Dev Immunol 2013: 403121. http://dx.doi.org/10.1155/2013/403121.
81. Goldstein E, Viboud C, Charu V, Lipsitch M. 2012. Improving the estimation of influenza-related mortality over a seasonal baseline. Epidemiology 23: 829-838. http://dx.doi.org/10.1097/EDE.0b013e31826c2dda.
82. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji ST, Aide P, Anderson S, Ansong D, Aponte JJ, Asante KP, Bejon P, Birkett AJ, Bruls M, Connolly KM. 2015. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med 373: 2025-2037. http://dx.doi.org/10.1056/NEJMoa1505819.
83. Henriques-Normark B, Normark S. 2014. Bacterial vaccines and antibiotic resistance. Ups J Med Sci 119: 205-208. http://dx.doi.org/10.3109/03009734.2014.903324.
84. Trzcinski K, Thompson CM, Gilbey AM, Dowson CG, Lipsitch M. 2006. Incremental increase in fitness cost with increased beta-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J Infect Dis 193: 1296-1303. http://dx.doi.org/10.1086/501367.
85. Li Y, Gierahn T, Thompson CM, Trzciń ski K, Ford CB, Croucher N, Gouveia P, Flechtner JB, Malley R, Lipsitch M. 2012. Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathog 8: e1002989. http://dx.doi.org/10.1371/journal.ppat.1002989.
86. Hoffman SJ, Caleo GM, Daulaire N, Elbe S, Matsoso P, Mossialos E, Rizvi Z, Røttingen JA. 2015. Strategies for achieving global collective action on antimicrobial resistance. Bull World Health Organ 93: 867-876. http://dx.doi.org/10.2471/BLT.15.153171.
87. Kremer M, Snyder CM. 2015. Preventives versus treatments. Q J Econ 130: 1167-1239.